Efficacy of Lanadelumab in Hereditary Angioedema Patients Switching From C1 Inhibitor Long-Term Prophylaxis: Interim Results From the HELP Open-Label Extension Study

被引：0
|
作者：
Riedl, Marc A. [1 ]
Anderson, John T. [2 ]
Cicardi, Marco [3 ]
Li, H. Henry [4 ]
Lockey, Richard F. [5 ]
Longhurst, Hilary [6 ,7 ]
Maurer, Marcus [8 ]
Lu, Peng [9 ]
Hao, James [9 ]
Banerji, Aleena [10 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Clin Res Ctr Alabama, Birmingham, AL USA
[3] Univ Milan, Dept Biomed & Clin Sci, Luigi Sacco Hosp, ASST Fatebenefratelli Sacco, Milan, Italy
[4] Inst Asthma & Allergy, Chevy Chase, MD USA
[5] Univ S Florida, Morsani Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL USA
[6] Cambridge Univ Hosp NHS Fdn Trust, Dept Immunol, Addenbrookes Hosp, Cambridge, England
[7] Barts Hlth NHS Trust, Dept Immunol, London, England
[8] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[9] Shire, Lexington, MA USA
[10] Harvard Med Sch, Div Rheumatol Allergy & Immunol, Dept Med, Massachusetts Gen Hosp, Boston, MA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
112
引用
收藏
页码：AB38 / AB38
页数：1
相关论文
共 50 条
  • [21] LONG-TERM EFFICACY OF SUBCUTANEOUS C1 INHIBITOR IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA
    Manning, M.
    Caballero, T.
    Hussain, I.
    Feuersenger, H.
    Chiao, J.
    Jacobs, I.
    Pragst, I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S31 - S32
  • [22] Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
    Levy, Donald
    Caballero, Teresa
    Hussain, Iftikhar
    Reshef, Avner
    Anderson, John
    Baker, James
    Schwartz, Lawrence B.
    Cicardi, Marco
    Prusty, Subhransu
    Feuersenger, Henrike
    Pragst, Ingo
    Manning, Michael E.
    PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2020, 33 (03) : 136 - 141
  • [23] Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open- Label Extension Study
    Riedl, Marc
    Anderson, John
    Arcoleo, Francesco
    Cancian, Mauro
    Chapdelaine, Hugo
    Conlon, Niall
    Eren, Efrem
    Gompels, Mark
    Grigoriadou, Sofia
    Guarino, Maria
    Gurugam, Padmalal
    Kinaciyan, Tamar
    Magerl, Markus
    Manning, Michael
    Stobiecki, Marcin
    Tarzi, Michael
    Valerieva, Anna
    Wedner, H. James
    Yang, William
    Zanichelli, Andrea
    Crabbe, Rafael
    Mulders, Susan
    Levy, Jonathan
    Freudensprung, Ulrich
    Katbeh, Umar
    Knolle, Jochen
    Lesage, Anne
    Lu, Peng
    Aygoeren-Puersuen, Emel
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB194 - AB194
  • [24] Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
    Levy, Donald S.
    Farkas, Henriette
    Riedl, Marc A.
    Hsu, Florence Ida
    Brooks, Joel P.
    Cicardi, Marco
    Feuersenger, Henrike
    Pragst, Ingo
    Reshef, Avner
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2020, 16 (01)
  • [25] Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
    Donald S. Levy
    Henriette Farkas
    Marc A. Riedl
    Florence Ida Hsu
    Joel P. Brooks
    Marco Cicardi
    Henrike Feuersenger
    Ingo Pragst
    Avner Reshef
    Allergy, Asthma & Clinical Immunology, 16
  • [26] Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks
    Riedl, M.
    Zuraw, B.
    Baker, J.
    Hurewitz, D.
    White, M.
    Vegh, A.
    Bielory, L.
    Lumry, W.
    Davis-Lorton, M.
    Levy, R.
    Grant, A.
    Busse, P.
    Banerji, A.
    Li, H.
    Tillotson, G.
    Kalfus, I
    Broom, C.
    ALLERGY, 2011, 66 : 420 - 421
  • [27] LANADELUMAB REDUCES HAE ATTACK RATE: INTERIM FINDINGS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Bernstein, J.
    Yang, W.
    Longhurst, H.
    Magerl, M.
    Hebert, J.
    Shennak, M.
    Martinez-Saguer, I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S37 - S37
  • [28] DONIDALORSEN FOR HEREDITARY ANGIOEDEMA: RESULTS FROM THE OASISPLUS OPEN-LABEL EXTENSION STUDY
    Tachdjian, R.
    Riedl, M.
    Bordone, L.
    Newman, K.
    Treadwell, S.
    Lin, T.
    Yarlas, A.
    Cohn, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S38 - S38
  • [29] Long-term efficacy and safery of switching from Ustekinumab to Risankizuman: results from the open-label extension LIMMitless
    Strober, Bruce
    Eyerich, Killian
    Hong, H. Chih-Ho
    Zeng, Jiewei
    Valdecantos, Wendell C.
    Valdes, Joaquin
    Bachelez, Herve
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 19 - 19
  • [30] A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design
    Riedl, M.
    Bernstein, J. A.
    Craig, T.
    Banerji, A.
    Magerl, M.
    Cicardi, M.
    Longhurst, H. J.
    Shennak, M.
    Yang, W.
    Schranz, J.
    Baptista, J.
    Busse, P.
    ALLERGY, 2017, 72 : 598 - 599
12345